Cabrerizo María, Fernández-García Mª Dolores
Laboratorio Nacional de Polio / Laboratorio de Enterovirus y Virus productores de Gastroenteritis; Centro Nacional de Microbiología; Instituto de Salud Carlos III. Madrid. España.
CIBER de epidemiología y salud pública. Madrid. España.
Rev Esp Salud Publica. 2025 Mar 21;99:e202503016.
The aim of this paper was to describe the activities carried out by the National Poliovirus Laboratory (LNP) and the Spanish Acute Flaccid Paralysis (AFP) Surveillance Network. The LNP coordinates the network since 1998 and is responsible for the characterization of polioviruses (PV) and other enteroviruses (EV) detected, using cell culture and molecular methods. It is annually accredited by WHO and represents Spain in the World Health Organization European Polio Laboratory Network. In addition to the reported AFP cases, the network has analyzed since its creation an average of 9,000 clinical samples annually for EV, with a 7% of positive results. Two surveillance periods can be distinguished in Spain: from 1998 to 2004, when vaccine PV could be detected due to the use of the oral polio vaccine, and from 2005 onwards, when only three cases of imported vaccine-derived poliovirus have been identified following the introduction of the inactivated polio vaccine. In addition, between 70% and 85% of the EV samples received at the LNP are successfully genotyped. The work carried out by the lab network has contributed to the epidemiological and clinical surveillance and research of these infections, as well as to the rapid detection and characterization of imported poliomyelitis cases. This has facilitated the timely implementation of appropriate measures to prevent PV transmission and circulation in our country, in alignment with the Global Polio Eradication Initiative.
本文旨在描述国家脊髓灰质炎病毒实验室(LNP)和西班牙急性弛缓性麻痹(AFP)监测网络开展的活动。自1998年以来,LNP负责协调该网络,并负责使用细胞培养和分子方法对检测到的脊髓灰质炎病毒(PV)和其他肠道病毒(EV)进行特征分析。它每年都获得世界卫生组织的认可,并代表西班牙参与世界卫生组织欧洲脊髓灰质炎实验室网络。除了报告的AFP病例外,该网络自成立以来每年平均分析9000份临床样本以检测EV,阳性结果率为7%。西班牙可分为两个监测期:1998年至2004年,由于使用口服脊髓灰质炎疫苗,可检测到疫苗衍生的PV;2005年起,在引入灭活脊髓灰质炎疫苗后,仅发现3例输入性疫苗衍生脊髓灰质炎病毒病例。此外,LNP收到的EV样本中有70%至85%成功进行了基因分型。该实验室网络开展的工作有助于对这些感染进行流行病学和临床监测与研究,以及对输入性脊髓灰质炎病例进行快速检测和特征分析。这有助于及时采取适当措施,以防止PV在我国传播和流行,符合全球消灭脊髓灰质炎倡议。